Join

Compare · SEAS vs SLNO

SEAS vs SLNO

Side-by-side comparison of SeaWorld Entertainment Inc. (SEAS) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both SEAS and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
  • SEAS is the larger of the two at $4.50B, about 1.6x SLNO ($2.76B).
  • SLNO has hit the wire 39 times in the past 4 weeks while SEAS has been quiet.
  • SEAS has more recent analyst coverage (16 ratings vs 12 for SLNO).
MetricSEASSLNO
Company
SeaWorld Entertainment Inc.
Soleno Therapeutics Inc.
Price
$50.34+2.56%
$53.02+0.08%
Market cap
$4.50B
$2.76B
1M return
-
+0.76%
1Y return
-
-31.78%
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Exchange
NYSE
NASDAQ
IPO
2013
2014
News (4w)
0
39
Recent ratings
16
12
SEAS

SeaWorld Entertainment Inc.

SeaWorld Entertainment, Inc., together with its subsidiaries, operates as a theme park and entertainment company in the United States. The company operates SeaWorld theme parks in Orlando, Florida; San Antonio, Texas; and San Diego, California, as well as Busch Gardens theme parks in Tampa, Florida, and Williamsburg, Virginia. It also operates water park attractions in Orlando, Florida; San Antonio, Texas; Chula Vista, California; Tampa, Florida; and Williamsburg, Virginia. In addition, the company operates a reservations-only theme park in Orlando, Florida and a seasonal park in Langhorne, Pennsylvania. It operates a portfolio of twelve theme parks under the SeaWorld, Busch Gardens, Aquatica, Discovery Cove, Water Country USA, Adventure Island, and Sesame Place brands. The company was formerly known as SW Holdco, Inc. and changed its name to SeaWorld Entertainment, Inc. in December 2012. SeaWorld Entertainment, Inc. was founded in 1959 and is headquartered in Orlando, Florida.

SLNO

Soleno Therapeutics Inc.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Latest SEAS

Latest SLNO